Canine freeze-dried plasma could expand access to dog transfusions

Version 2

A new shelf-stable transfusion product could widen where dogs receive plasma support. Mantel Technologies’ canine freeze-dried plasma is now on the U.S. market after the FDA completed a risk review on December 18, 2025, concluding that the product’s risks were appropriately mitigated and that the agency did not intend to object to marketing it. The product is intended for treatment of hypovolemia and control of hemorrhage in dogs, and it can be stored for at least one year without the cold-chain requirements that come with conventional plasma products. (fda.gov)

That logistical difference is the real story. Fresh frozen plasma and related products typically require refrigerated or frozen storage, limited shelf-life management, and thaw time before administration. Those constraints can make plasma difficult to keep on hand in small practices, during transport, in remote environments, or in military and disaster-response settings. FDA specifically noted that cFDP may be useful in acute emergencies when whole blood products are not available, including trauma cases involving military working dogs and dogs in remote locations. The military connection is longstanding: federal SBIR records show the product was developed in part to support field care for military working dogs. (fda.gov)

Regulatorily, cFDP sits in an unusual category. FDA says the product is not approved, conditionally approved, or index listed. Instead, it was reviewed as an animal cell, tissue, and cell- and tissue-based product, or ACTP, and allowed to enter the market after the agency determined the risks were low and appropriately mitigated. The product is available by prescription only through a licensed veterinarian, and FDA says specialized veterinary expertise is necessary for safe use. Each kit includes a single-use 250 mL plasma unit, 250 mL sterile water for injection, and a blood administration set. The plasma is pooled allogeneic canine plasma, offered in DEA 1 negative or DEA 1 positive variants. (fda.gov)

FDA’s risk assessment offers some of the clearest detail on what evidence supported the launch. The agency reviewed product characterization, manufacturing controls, donor eligibility, published literature, and company studies. In the safety package, Mantel conducted three studies involving 46 dogs that received 20 mL/kg IV. Those studies looked at overall safety, use across blood groups, hemorrhage control in induced coagulopathy, and treatment of hypovolemia after blood loss. FDA said adverse events were infrequent and generally aligned with known plasma-transfusion risks, including cutaneous hypersensitivity reactions and vomiting. (fda.gov)

The broader clinical rationale has been building for years. A 2021 review in Frontiers in Veterinary Science argued that freeze-dried plasma was likely to have wide application in veterinary hemostatic resuscitation because of its logistical advantages. More recent laboratory work has also supported the concept, with a 2025 Frontiers study reporting preserved stability and coagulation-related performance characteristics consistent with use as a rapid resuscitative product, though that work was in vitro and does not substitute for clinical outcomes data. Meanwhile, an AAHA Trends article this spring highlighted likely real-world use cases in practices that don’t maintain blood banks but still see emergencies such as trauma, severe hemorrhage, rodenticide toxicity, or coagulopathies. (frontiersin.org)

Why it matters: For veterinary professionals, cFDP could narrow a longstanding access gap in transfusion medicine. Emergency and critical care teams already know plasma can be lifesaving, but many dogs present first to clinics that lack freezer capacity, blood product inventory, or immediate referral options. A shelf-stable kit won’t replace comprehensive transfusion services, and it still requires veterinary judgment, IV administration, and monitoring for transfusion reactions. But it could make earlier plasma-based stabilization more realistic in general practice, urgent care, mobile response, and rural settings, particularly when time lost to sourcing and thawing plasma can shape outcomes. (fda.gov)

There are still practical questions. Availability may be uneven at first; Mantel’s online store has recently shown some kit variants as sold out or unavailable, suggesting supply could be a near-term constraint. And because the product entered the market through FDA’s ACTP risk-review pathway rather than a conventional approval process, clinicians and buyers will likely want more post-market experience, protocol development, and published field data to clarify where cFDP fits relative to fresh frozen plasma, thawed plasma, whole blood, and referral-based transfusion care. (store.manteltechnologies.com)

What to watch: The next phase will be less about regulatory clearance and more about uptake: whether emergency and referral hospitals add cFDP to protocols, whether smaller clinics stock it for stabilization before transfer, and whether post-market data confirm that the product’s logistical advantages translate into faster, broader access to plasma transfusion for dogs. (fda.gov)